{"schema_version":"1.0","type":"article","title":"全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價","url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.md","lang":"zh-Hant","date":"2026-05-23","publish_at":"2026-05-23T10:30:00+08:00","updated_at":"2026-05-23","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","藥華藥","減重藥","生技投資"],"summary":"當台灣資本市場的資金與目光被 AI 半導體全面虹吸時，全球生技產業正悄悄用另一種方式重新定義人類的未來——那就是減肥藥的瘋狂狂潮。我們多次提到，AI 解決的是算力與效率問題，而生技醫療解決的是疾病與生","key_points":[],"facts":[],"sections":["01｜限時超強早鳥：第一階段最高折抵開跑","02｜四大核心獲利模組：從科學結構到法人定價","03｜ 投資不是看運氣，而是建立一套你看得懂的系統"],"references":[],"images":[{"alt":"Dcard 原圖：全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價","url":"https://drugnews.com.tw/assets/articles/global-biotech-obesity-megatrend/dcard-01.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/global-biotech-obesity-megatrend/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-23）。全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價。https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-23-global-biotech-obesity-megatrend-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}